NAS President Shifts Gears In Plea For More Funding

WASHINGTON—What goes from zero to $10 billion in one year? National Academy of Sciences president Frank Press’s solution to the problems facing the scientific community. Last spring, Press delivered a stem talk to academy members about the need to set scientific priorities. The federal budget is a zero-sum game, he warned them, and the scientific community had better decide what’s most important before Congress acts for purely political reasons. That speech was widely a

Written byJeffrey Mervis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON—What goes from zero to $10 billion in one year? National Academy of Sciences president Frank Press’s solution to the problems facing the scientific community.

Last spring, Press delivered a stem talk to academy members about the need to set scientific priorities. The federal budget is a zero-sum game, he warned them, and the scientific community had better decide what’s most important before Congress acts for purely political reasons.

That speech was widely applauded as along-overdue attempt to bring ivory tower scientists in touch with the real world of $150 billion budget deficits. Although some segments of the community— notably proponents of the space station and the superconducting supercollider—felt that their pet projects were being attacked, the consensus was that the time had come to talk about what was affordable, not just what was possible. Congress was similarly impressed, with the Senate Budget Committee asking the academy to suggest a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies